Researchers have found that a bacterium that emerged centuries ago in Europe has now been spreading globally into countries undergoing rapid development and industrialization. Unlike other diarrheal diseases, this one is unlikely to be resolved by providing access to clean water. As developing countries become more industrialized the numbers of infections with dysentery-causing Shigella flexneri are known to decline, associated with improved health, lifestyle and perhaps most importantly access to clean water, but the incidence of another form of the dysentery-causing bacterium, Shigella sonnei, actually increases.
The team pinpointed that S. sonnei was first established in Europe just a few centuries ago, but in the last few decades has spread to the rest of the world. They also found that a key factor in the spread of this pathogen was a rise in multidrug resistance - the ability to survive exposure to a wide array of antibiotics. Because S. sonnei is easily transmitted and has high levels of drug resistance, the researchers suggest that drug treatment and better sanitation alone will not be sufficient for controlling the disease. Vaccine development will be crucial.
Dysentery is a disease primarily associated with developing countries and more than one million people, mostly young children, are estimated to die from dysentery caused by Shigella each year. Whilst most people have heard about dysentery, few know about the bacteria that causes it, Shigella. This is because it is relatively understudied and little is known about their population structure or its origins. Traditionally, S. flexneri has been the most common form of Shigella bacterium to cause dysentery in developing countries with S. sonnei more prevalent in industrialized countries. Yet, this is beginning to change with S. sonnei becoming increasingly common as developing countries rapidly industrialize.
"Although S. sonnei is a relatively new species of bacterium, during its spread it has diversified into an array of different distinguishable clones or strains found right across the world," says Dr Kathryn Holt, first author from the University of Melbourne. "This is hard to see using traditional methods, but by sequencing the genomes of over 100 different forms of the bacteria, we were able to get a glimpse into its past and really start to understand how it is evolving and moving around the world."
"We compared the S. sonnei family tree and geographical locations of the different strains to determine when and where this bacterium first emerged and why it has become such a problem in industrialized countries with increasing access to clean water. Traditionally we associate dysentery with contaminated water and lack of industrialization."
To investigate why the bacterium was spreading so effectively, the team looked at the S. sonnei's genetic evolution and found that only a few types of genes were selectively evolving over time, particularly those involved with drug resistance. This suggests that a major driver in the spread of this bacterium was its apparent ability to become resistant to drug treatment.
"Since S. sonnei originated, we found there have been three, independent, yet closely related lineages that have spread. The two most recent lineages have been continually evolving to become increasingly resistant to antimicrobials," says Dr Stephen Baker, a senior author from the Oxford University Clinical Research Unit in Vietnam. "Our data is consistent with antibiotic resistance as being a main driver of the spread and persistence of S.sonnei around the world, stressing that antibiotics are not a long-term solution for the elimination of this global health problem."
Despite the fact S. sonnei and S. flexneri are closely related they have very different surface antigens or coats that interact with the human immune system. S. sonnei has only one type of outer coat, while S. flexneri has many, all of which look very different from that of S. sonnei. It has been speculated for some time that S. sonnei acquired its outer coat from another bacterium that is commonly found in contaminated water, Plesiomonas shigelloides.
Both S. sonnei and P. shigelloides have an identical outer coat. It is believed that when a person is exposed to contaminated water containing P. shigelloides, there is an immune cross reaction and the body builds a natural immunity against S. sonnei. This theory may explain why the incidence of S. sonnei increases following economic development and improvements to water quality, and is consistent with the patterns of global spread described in the current report.
"One of the Millennium Development Goals is to improve drinking water and reduce water borne diseases, an undeniably important aim," says Professor Nicholas Thomson, lead author from the Wellcome Trust Sanger Institute. "This may have the unforeseen result of increasing the incidence of S. sonnei dysentery in transitional countries.
"Our research emphasises the importance of a vaccine against Shigella. The combination of increased incidence and antibiotic resistance of S. sonnei, means that a vaccine will be increasingly important for the long-term control and prevention of dysentery."
Notes to Editors
Kathryn E. Holt, Stephen Baker, François-Xavier Weill, Edward C. Holmes, Andrew Kitchen, Jun Yu, Vartul Sangal, Derek J. Brown, John E. Coia, Dong Wook Kim, Seon Young Choi, Su Hee Kim, Wanderley D. da Silveir, Derek J. Pickard, Jeremy J. Farrar, Julian Parkhill, Gordon Dougan, Nicholas R. Thomson
'Out of Europe: The recent global dissemination of Shigella sonnei'
Published in Nature Genetics online on August 5 2012 DOI: XX XX
This work was supported by the Wellcome Trust and a Victorian Life Sciences Computation Initiative (VLSCI) grant on its Peak Computing Facility at the University of Melbourne, an initiative of the Victorian Government,
- University of Melbourne, Department of Microbiology and Immunology, Royal Parade, Melbourne, Victoria, 3010, Australia
- The Hospital for Tropical Diseases, Wellcome Trust Major Overseas Programme, Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam
- Institut Pasteur, Unité des Bactéries Pathogènes Entériques, Paris, France
- Center for Infectious Disease Dynamics, Department of Biology, The Pennsylvania State University, University Park, PA 16802, USA
- Fogarty International Center, National Institutes of Health, Bethesda, MD 20892, USA
- Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, G4 0RE, UK
- Scottish Salmonella, Shigella and Clostridium difficile Reference Laboratory, Stobhill Hospital, 133 Balornock Road, Glasgow, UK
- Molecular Biology Laboratory, International Vaccine Institute (IVI), Seoul, Republic of Korea
- Department of Pharmacy, College of Pharmacy, Hanyang University
- Ansan, Kyeonggi- do, 426-791, KoreaDepartment of Genetics, Evolution and Bioagents, Biology Institute, Campinas State
- University - UNICAMP, BrazilWellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK CB10 1SA
Oxford University's Medical Sciences Division is one of the largest biomedical research centres in Europe, with over 2,500 people involved in research and more than 2,800 students. The University is rated the best in the world for medicine, and it is home to the UK's top-ranked medical school.
From the genetic and molecular basis of disease to the latest advances in neuroscience, Oxford is at the forefront of medical research. It has one of the largest clinical trial portfolios in the UK and great expertise in taking discoveries from the lab into the clinic. Partnerships with the local NHS Trusts enable patients to benefit from close links between medical research and healthcare delivery.
A great strength of Oxford medicine is its long-standing network of clinical research units in Asia and Africa, enabling world-leading research on the most pressing global health challenges such as malaria, TB, HIV/AIDS and flu. Oxford is also renowned for its large-scale studies which examine the role of factors such as smoking, alcohol and diet on cancer, heart disease and other conditions. www.ox.ac.uk
The Wellcome Trust Sanger Institute is one of the world's leading genome centres. Through its ability to conduct research at scale, it is able to engage in bold and long-term exploratory projects that are designed to influence and empower medical science globally. Institute research findings, generated through its own research programmes and through its leading role in international consortia, are being used to develop new diagnostics and treatments for human disease.
The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. We support the brightest minds in biomedical research and the medical humanities. Our breadth of support includes public engagement, education and the application of research to improve health. We are independent of both political and commercial interests.
Don Powell Media Manager
Wellcome Trust Sanger Institute
Hinxton, Cambridge, CB10 1SA, UK
Tel +44 (0)1223 496 928
Mobile +44 (0)7753 7753 97